Several possible studies
Story checked
Lilly's 'triple-G' drug bests Ozempic in head to head study | STAT (opens in a new tab)
statnews.com · 2026-10-28
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Lilly's 'triple-G' drug bests Ozempic in head to head study | STAT
statnews.com · 2026-10-28
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedEli Lilly said its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 4Not checkedIn the head-to-head study, people on the highest dose of retatrutide saw a 2.2 percentage-point reduction in A1c after 80 weeks, compared with a 1.8 percentage-point reduction for people on Ozempic.View evidenceHide evidence
As stated2.2 percentage-point reduction vs 1.8 percentage-point reduction after 80 weeks
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 4Not checkedParticipants on the highest dose of retatrutide lost 20.9% of their weight, while those taking Ozempic lost 9.4%.View evidenceHide evidence
As stated20.9% weight loss vs 9.4% weight loss
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 4Not checkedThe reported results were based on analyses of participants who stayed on treatment, not all participants.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Acta Diabetologica · 2026 · PubMed
Early improvement of HbA1c, weight and low-density lipoprotein (LDL) for Type 2 diabetes (T2D) patient by Rybelsus (oral semaglutide)
International Journal of Endocrinology and Diabetes · 2022 · Crossref
Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence
2026 · Europe PMC
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition · 2026 · PubMed
Significant effect of decreased weight and HbA1c by oral semaglutide (Rybelsus) for Type 2 Diabetes (T2D) patient
International Journal of Endocrinology and Diabetes · 2023 · Crossref